Aspirin Use Is Associated With Decreased Inpatient Mortality in Patients With COVID-19: A Meta-Analysis

Authors

Aswin Srinivasan
Jonathan Brown
Pavitra Parimala Krishnamani
Brendon Cornett
Ramesh Babu Kesavan
Siva T Sarva
Syed Arman Raza
Waleed Tallat Kayani

Publication Date

8-1-2022

Journal

American Heart Journal Plus: Cardiology Research and Practice

DOI

10.1016/j.ahjo.2022.100191

PMID

35971534

PMCID

PMC9365516

PubMedCentral® Posted Date

8-11-2022

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Keywords

Aspirin, COVID-19, Mortality, Anti-thrombotic therapy, Thromboembolism

Abstract

Thromboembolism is a major cause of death in patients who suffer from COVID-19. Studies examining the effects of aspirin (ASA) on mortality relating to this phenomenon have showed conflicting results with varying degrees and certainties of evidence. We performed an aggregate data meta-analysis of fourteen studies encompassing 164,539 COVID-19 patients, which showed a reduced risk of in-hospital mortality associated with ASA use in eight studies that reported risk ratios (RR 0.90; 95 % CI 0.82–0.98; I2 = 27.33 %, P = 0.01), six studies that reported hazard ratios (HR 0.56; 95 % CI 0.41–0.76, P ≤ 0.01; I2 = 85.92 %) and pooled effect size (0.71; 95 % CI 0.59–0.85, P = 0.00, I2 = 91.51 %). The objective of this study is to report the association between low dose ASA and a reduced risk of in-hospital mortality in patients with COVID-19.

Comments

Associated Data